Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018)

2019 ◽  
Vol 29 (6) ◽  
pp. 407-427 ◽  
Author(s):  
Sayyed Mohammad Ismail Mahboubi Rabbani ◽  
Afshin Zarghi
2019 ◽  
Vol 24 (3) ◽  
pp. 673-689 ◽  
Author(s):  
Sevil Şenkardeş ◽  
M. İhsan Han ◽  
Necla Kulabaş ◽  
Mürüvvet Abbak ◽  
Özge Çevik ◽  
...  

Nanomedicine ◽  
2021 ◽  
Author(s):  
Asmaa F Khafaga ◽  
Rehab N Shamma ◽  
Ahmed Abdeen ◽  
Abdelmonem M Barakat ◽  
Ahmed E Noreldin ◽  
...  

While cancer remains a significant global health problem, advances in cancer biology, deep understanding of its underlaying mechanism and identification of specific molecular targets allowed the development of new therapeutic options. Drug repurposing poses several advantages as reduced cost and better safety compared with new compounds development. COX-2 inhibitors are one of the most promising drug classes for repurposing in cancer therapy. In this review, we provide an overview of the detailed mechanism and rationale of COX-2 inhibitors as anticancer agents and we highlight the most promising research efforts on nanotechnological approaches to enhance COX-2 inhibitors delivery with special focus on celecoxib as the most widely studied agent for chemoprevention or combined with chemotherapeutic and herbal drugs for combating various cancers.


2001 ◽  
Vol 120 (5) ◽  
pp. A143-A144
Author(s):  
S KATO ◽  
Y OGAWA ◽  
T KUNIKATA ◽  
T WATANABE ◽  
T ARAKAWA ◽  
...  

2015 ◽  
Vol 11 (2) ◽  
pp. 188-199 ◽  
Author(s):  
Ankita Rathore ◽  
Mujeeb-Ur-Rahman ◽  
Anees A. Siddiqui ◽  
Abuzer Ali ◽  
Mohammad Shahar Yar

Sign in / Sign up

Export Citation Format

Share Document